Literature DB >> 24899072

[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].

Mélanie Bruchard1, François Ghiringhelli2.   

Abstract

MDSC (myeloid derived suppressor cells) are immature cells from myeloid origin that accumulate in spleen and tumor bed during tumor growth and that can suppress anti-tumor immunity by various ways. Two chemotherapeutic agents, 5-fluorouracil and gemcitabin, that are commonly used in the treatment of colon cancer and pancreatic cancer, can selectively kill MDSC. Beneficial effects of 5-Fluorouracil and gemcitabin are however temporary. After treatment with those chemotherapies, an activation of the NLRP3 inflammasome is observed in MDSC, due to an interaction between cathepsin B and NLRP3, which leads to the production of IL-1β thus increasing pro-tumor immune responses. IL-1β enhances the production of IL-17 by CD4 T cells which in turn favors angiogenesis and tumor growth.

Entities:  

Keywords:  chemoresistant tumor; inflammasome; myeloid cells

Mesh:

Substances:

Year:  2014        PMID: 24899072     DOI: 10.1684/bdc.2014.1936

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  10 in total

1.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

2.  Functional analysis of CD14+HLA-DR-/low myeloid-derived suppressor cells in patients with lung squamous cell carcinoma.

Authors:  Yun Chen; Guichang Pan; Dongbo Tian; Yifei Zhang; Taoping Li
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

Review 3.  Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Cancer Res       Date:  2019-08-20       Impact factor: 12.701

4.  Myeloid Derived Suppressor Cells: Fuel the Fire.

Authors:  B R Achyut; Ali S Arbab
Journal:  Biochem Physiol       Date:  2014-06-23

5.  Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma.

Authors:  Catherine Westbom; Joyce K Thompson; Alan Leggett; Maximilian MacPherson; Stacie Beuschel; Harvey Pass; Pamela Vacek; Arti Shukla
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

6.  Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.

Authors:  Wen-Ying Zhang; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Qing-Ming Yang; Ya-Jing Zhang; Yan Zhang; Mei-Xia Chen; Chun-Meng Wang; Kai-Chao Feng; Su-Xia Li; Yang Liu; Feng-Xia Shi; Can Luo; Wei-Dong Han
Journal:  Signal Transduct Target Ther       Date:  2016-03-11

Review 7.  Inflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy.

Authors:  Dev Karan
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

Review 8.  Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.

Authors:  Jean-David Fumet; Emeric Limagne; Marion Thibaudin; Francois Ghiringhelli
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

9.  Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator.

Authors:  Han Zhang; Ze-Lei Li; Shu-Biao Ye; Li-Ying Ouyang; Yu-Shan Chen; Jia He; Hui-Qiang Huang; Yi-Xin Zeng; Xiao-Shi Zhang; Jiang Li
Journal:  Cancer Immunol Immunother       Date:  2015-10-23       Impact factor: 6.968

10.  CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.

Authors:  Kaiming Ma; Xin Chen; Weihai Liu; Suhua Chen; Chenlong Yang; Jun Yang
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.